{"disease":{"id":"ocular-hypertension","name":"Ocular hypertension","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":30,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"nab-paclitaxel","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"nab-paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":57,"revenue":"368","mechanism":""},{"drug_id":"paclitaxel","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor [EPC]","quality_score":76,"revenue":"368","mechanism":""},{"drug_id":"nabpaclitaxel","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"Nabpaclitaxel","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":null,"revenue":"368","mechanism":"Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division."},{"drug_id":"brimonidine","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alphagan","generic_name":"BRIMONIDINE","company_name":"Senju Pharmaceutical Co., Ltd","drug_phase":"marketed","molecular_target":"Alpha-2C adrenergic receptor","drug_class":"alpha-Adrenergic Agonist","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"levobetaxolol","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betaxon","generic_name":"LEVOBETAXOLOL","company_name":"Alcon Pharms Ltd","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"levobetaxolol","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"azopt","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Azopt","company_name":"Alcon Research","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 13","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"mannitol-20","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mannitol","generic_name":"Mannitol","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Glomerular filtrate osmolarity; intracellular water movement","drug_class":"Osmotic diuretic","quality_score":66,"revenue":null,"mechanism":"Osmotic diuretic that elevates glomerular filtrate osmolarity to inhibit tubular water reabsorption."},{"drug_id":"befunolol","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bentos","generic_name":"BEFUNOLOL","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"befunolol","quality_score":null,"revenue":null,"mechanism":"Bentos works by reducing the production of fluid in the eye, thereby lowering intraocular pressure."},{"drug_id":"isobide","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Isobide","company_name":"Alvogen Korea","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"metipranolol","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Optipranolol","generic_name":"METIPRANOLOL","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"brinzolamide","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azopt","generic_name":"BRINZOLAMIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"carbonic anhydrase II","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":48,"revenue":null,"mechanism":"Brinzolamide reduces intraocular pressure by inhibiting carbonic anhydrase II, decreasing aqueous humor secretion."},{"drug_id":"xalatan","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xalatan","company_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","drug_phase":"marketed","molecular_target":"Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"latanoprost","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xalatan","generic_name":"LATANOPROST","company_name":"Thea Pharma","drug_phase":"marketed","molecular_target":"Prostaglandin F2-alpha receptor","drug_class":"Prostaglandin Analog [EPC]","quality_score":75,"revenue":null,"mechanism":"Xalatan works by increasing the outflow of fluid from the eye, reducing pressure."},{"drug_id":"travoprost","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Travatan","generic_name":"TRAVOPROST","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin F2-alpha receptor","drug_class":"Prostaglandin Analog [EPC]","quality_score":10,"revenue":null,"mechanism":"Travatan works by increasing the outflow of fluid from the eye to reduce pressure."},{"drug_id":"bimatoprost","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lumigan","generic_name":"BIMATOPROST","company_name":"","drug_phase":"marketed","molecular_target":"Aldo-keto reductase family 1 member C3","drug_class":"Prostaglandin Analog [EPC]","quality_score":75,"revenue":null,"mechanism":"Lumigan works by increasing the outflow of fluid from the eye to reduce pressure."},{"drug_id":"carteolol","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ocupress","generic_name":"CARTEOLOL","company_name":"","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"isosorbide","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isobide","generic_name":"ISOSORBIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"Nitrate Vasodilator [EPC]","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"pilocarpine","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Salagen","generic_name":"PILOCARPINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"Cholinergic Receptor Agonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"latanoprostene-bunod","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyzulta","generic_name":"LATANOPROSTENE BUNOD","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Prostaglandin F2-alpha receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Vyzulta works by activating the Prostaglandin F2-alpha receptor, which increases the outflow of aqueous humor from the eye, thereby reducing intraocular pressure."},{"drug_id":"mannitol","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aridol Kit","generic_name":"MANNITOL","company_name":"Baxter","drug_phase":"marketed","molecular_target":"sodium channels","drug_class":"Osmotic Diuretic [EPC]","quality_score":75,"revenue":null,"mechanism":"Mannitol works by drawing water into the bloodstream from surrounding tissues, increasing urine production and reducing fluid accumulation in the body."},{"drug_id":"netarsudil","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rhopressa","generic_name":"NETARSUDIL","company_name":"Alcon Labs Inc","drug_phase":"marketed","molecular_target":"rho kinase","drug_class":"Rho Kinase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Netarsudil reduces intraocular pressure by increasing aqueous humor outflow through the trabecular meshwork."},{"drug_id":"betaxolol","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betoptic","generic_name":"BETAXOLOL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":10,"revenue":null,"mechanism":"Betaxolol works by blocking the beta-1 adrenergic receptor in the heart and eyes, reducing heart rate and pressure, and decreasing intraocular pressure."},{"drug_id":"glanatec","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Glanatec","company_name":"Michael D. Straiko, MD","drug_phase":"phase_2","molecular_target":"Serine/threonine-protein kinase TAO3, 5'-AMP-activated protein kinase subunit gamma-1, Aurora kinase B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"travatan","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Travatan","company_name":"Alcon Research","drug_phase":"marketed","molecular_target":"Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"abraxane","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abraxane","company_name":"The First Affiliated Hospital with Nanjing Medical University","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"salagen","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Salagen","company_name":"Alberta Health services","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"brimonidine-tartrate","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alphagan","generic_name":"BRIMONIDINE TARTRATE","company_name":"Senju Pharmaceutical Co., Ltd","drug_phase":"marketed","molecular_target":"Alpha-2C adrenergic receptor","drug_class":"alpha-Adrenergic Agonist","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"taxol","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxol","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dorzolamide","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trusopt","generic_name":"DORZOLAMIDE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Carbonic Anhydrase Inhibitor","quality_score":51,"revenue":null,"mechanism":"Trusopt works by inhibiting the enzyme carbonic anhydrase 2, which is involved in the production of aqueous humor in the eye."},{"drug_id":"levobunolol","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betagan","generic_name":"LEVOBUNOLOL","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":30,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01853085","title":"A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons","phase":"","overall_status":"COMPLETED","enrollment_count":1830,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT06629649","title":"Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers","phase":"NA","overall_status":"RECRUITING","enrollment_count":1800,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT01999348","title":"A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting","phase":"","overall_status":"COMPLETED","enrollment_count":1553,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT06829810","title":"Long-term Outcomes of Glaucoma Surgery in a Real-life Setting: the Agora Registry Study","phase":"","overall_status":"COMPLETED","enrollment_count":1528,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT01298700","title":"Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":806,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT04967989","title":"Clarifying the Optimal Application of SLT Therapy Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":790,"lead_sponsor_name":"University of Pittsburgh","has_results":false},{"nct_id":"NCT02571712","title":"Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":750,"lead_sponsor_name":"Allergan","has_results":false},{"nct_id":"NCT02558400","title":"Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":718,"lead_sponsor_name":"Aerie Pharmaceuticals","has_results":true},{"nct_id":"NCT03395535","title":"Laser-1st vs Drops-1st for Glaucoma and Ocular Hypertension","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":718,"lead_sponsor_name":"Moorfields Eye Hospital NHS Foundation Trust","has_results":false},{"nct_id":"NCT04630808","title":"MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":696,"lead_sponsor_name":"Nicox Ophthalmics, Inc.","has_results":false},{"nct_id":"NCT04445519","title":"Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":691,"lead_sponsor_name":"Nicox Ophthalmics, Inc.","has_results":true},{"nct_id":"NCT05397600","title":"Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":684,"lead_sponsor_name":"Laboratoires Thea","has_results":false},{"nct_id":"NCT03450629","title":"Evaluation of Safety and Efficacy of PDP-716","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":682,"lead_sponsor_name":"Sun Pharma Advanced Research Company Limited","has_results":true},{"nct_id":"NCT01026831","title":"Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":643,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03896633","title":"Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":637,"lead_sponsor_name":"Bausch & Lomb Incorporated","has_results":true},{"nct_id":"NCT04972695","title":"Validation of an Automatic Analysis Algorithm of the Probability of Glaucoma From Optic Disc Images","phase":"","overall_status":"COMPLETED","enrollment_count":615,"lead_sponsor_name":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","has_results":false},{"nct_id":"NCT05022004","title":"A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":599,"lead_sponsor_name":"Sun Pharmaceutical Industries Limited","has_results":true},{"nct_id":"NCT01099774","title":"Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":597,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT02247804","title":"Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":594,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT03519386","title":"Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Glaukos Corporation","has_results":true},{"nct_id":"NCT02914509","title":"Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":565,"lead_sponsor_name":"Ocular Therapeutix, Inc.","has_results":true},{"nct_id":"NCT03868124","title":"Clinical Study Comparing Two Models of a Travoprost Intraocular Implant","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":560,"lead_sponsor_name":"Glaukos Corporation","has_results":true},{"nct_id":"NCT04898387","title":"Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":554,"lead_sponsor_name":"Laboratoires Thea","has_results":false},{"nct_id":"NCT02250651","title":"Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":528,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT03850782","title":"Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04024072","title":"To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":495,"lead_sponsor_name":"Padagis LLC","has_results":true},{"nct_id":"NCT02339584","title":"Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":493,"lead_sponsor_name":"Alcon Research","has_results":true},{"nct_id":"NCT03825380","title":"Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":485,"lead_sponsor_name":"Laboratoires Thea","has_results":true},{"nct_id":"NCT04944290","title":"To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":447,"lead_sponsor_name":"Padagis LLC","has_results":true},{"nct_id":"NCT03284853","title":"Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":436,"lead_sponsor_name":"Aerie Pharmaceuticals","has_results":true},{"nct_id":"NCT06441643","title":"Next Generation Rocklatan","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":426,"lead_sponsor_name":"Alcon Research","has_results":false},{"nct_id":"NCT03691649","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":426,"lead_sponsor_name":"Santen Inc.","has_results":true},{"nct_id":"NCT05181046","title":"Evaluation of Nanodropper-mediated Microdrops vs. Standard Drops of 0.5% Timolol Maleate in Glaucoma Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":420,"lead_sponsor_name":"Nanodropper, Inc.","has_results":false},{"nct_id":"NCT01749904","title":"Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":420,"lead_sponsor_name":"Bausch & Lomb Incorporated","has_results":true},{"nct_id":"NCT03691662","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":417,"lead_sponsor_name":"Santen Inc.","has_results":true},{"nct_id":"NCT03235232","title":"BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":406,"lead_sponsor_name":"EMS","has_results":false},{"nct_id":"NCT07218796","title":"Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"SpyGlass Pharma, Inc.","has_results":false},{"nct_id":"NCT07218783","title":"Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"SpyGlass Pharma, Inc.","has_results":false},{"nct_id":"NCT05159960","title":"Optimal Treatment Protocol for Selective Laser Trabeculoplasty - Repeat Trial","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT06827535","title":"Long-term Vascular, Functional and Morphological Changes in Glaucoma and Ocular Hypertensive Patients","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400,"lead_sponsor_name":"Mario Stirpe","has_results":false},{"nct_id":"NCT03798223","title":"Optimal Treatment Protocol for Selective Laser Trabeculoplasty","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT04133311","title":"A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":386,"lead_sponsor_name":"Santen SAS","has_results":true},{"nct_id":"NCT03762369","title":"A Clinical Study to Evaluate the Efficacy and Safety of CKD-351","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":384,"lead_sponsor_name":"Chong Kun Dang Pharmaceutical","has_results":false},{"nct_id":"NCT03250819","title":"Gene Polymorphisms of Corticosteroid-induced Ocular Hypertension","phase":"","overall_status":"COMPLETED","enrollment_count":370,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT02617459","title":"Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":366,"lead_sponsor_name":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","has_results":false},{"nct_id":"NCT01735214","title":"An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments","phase":"","overall_status":"COMPLETED","enrollment_count":358,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT06666855","title":"A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":345,"lead_sponsor_name":"Santen Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05495061","title":"A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":325,"lead_sponsor_name":"Santen Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04742283","title":"Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":323,"lead_sponsor_name":"Santen Inc.","has_results":true},{"nct_id":"NCT00572455","title":"Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":318,"lead_sponsor_name":"Pfizer","has_results":true}],"total":50},"guidelines":[{"drug_id":"mannitol-20","guideline_body":"FDA label","recommendation":"OSMITROL is indicated for the reduction of elevated intraocular pressure.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null},{"drug_id":"mannitol-25","guideline_body":"FDA label","recommendation":"OSMITROL is indicated for the reduction of elevated intraocular pressure.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null},{"drug_id":"mannitol-5","guideline_body":"FDA label","recommendation":"OSMITROL is indicated for the reduction of elevated intraocular pressure.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null},{"drug_id":"mannitol-10","guideline_body":"FDA label","recommendation":"OSMITROL is indicated for the reduction of elevated intraocular pressure.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null}],"source":"Drug Landscape verified database"}